autologous EBV-specific cytotoxic T cells + gemcitabine + carboplatin

This therapy is a **combination treatment** comprising autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells, gemcitabine, and carboplatin. - **Autologous EBV-specific cytotoxic T cells**: These are immune cells (T lymphocytes) collected from the patient, expanded and activated ex vivo to recognize and kill EBV-infected cells. This adoptive cell therapy is used for targeted immunotherapy of EBV-associated malignancies, including EBV-positive lymphoproliferative disease (EBV-LPD) and EBV-positive lymphomas, particularly in immunocompromised or post-transplant patients. They exert their effect through specific recognition of viral antigens expressed on malignant cells, driving cytotoxic immune responses directed at EBV-infected cells with minimal toxicity[1][2][3]. - **Gemcitabine**: A nucleoside analog cytotoxic small molecule chemotherapy agent, inhibiting DNA synthesis, commonly used for various solid tumors including lymphomas. - **Carboplatin**: A platinum-based chemotherapeutic agent, alkylating DNA and promoting apoptosis in rapidly dividing cells, also broadly used in cancer treatment. The combination aims to enhance antitumor activity by combining the immunotherapeutic effect of the T cells with the cytotoxic effects of chemotherapeutic agents. The exact clinical development stage of this specific triplet combination may vary, but each component is established with known mechanisms and clinical use, and combination strategies are currently being evaluated or used in advanced EBV-driven malignancies and refractory lymphomas[1][2][3].